J B CHEMICALS AND PHARMA
JBCHEPHARM · NSE · inactive
2,408.90
-97.10 (-3.87%)
as of 16 Jul 2026 close
Open
2,506.00
High
2,525.50
Low
2,380.00
Prev close
2,506.00
52w high
2,525.50
16 Jul 2026
52w low
1,638.50
26 Sept 2025
VWAP
2,418.56
Delivery %
66.8%
of volume
Volume 47.79 L · turnover ₹1155.88 Cr · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 02 Feb 1995
- Series
- EQ
- F&O
- No
- Status
- Inactive since 17 Jul 2026
Source: NSE equity master · as of 16 Jul 2026
Market cap
—
P/B
—
ROE (TTM)
17.1%
ROCE 23.0%
Debt / equity
0.00
P/E (TTM)
—
P/S (TTM)
—
Revenue TTM
₹4,148 cr
Net profit TTM
₹709 cr
Net margin TTM
17.1%
OPM 26.0%
EV / EBITDA
—
Interest cover
172.0×
Revenue growth
-4.8%
latest quarter YoY
Profit growth
-30.4%
latest quarter YoY
Dividend yield
—
₹22 / share · payout —
Consolidated · last four quarters to 2026-03-31 · balance sheet 2026-03-31 · tap a tile for the formula
Daily · NSE EOD
Bulk & block deals · NSE daily reports
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.34 |
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.00 |
| 27 Mar 2025 | bulk | KOTAK MAHINDRA MUTUAL FUND | BUY | 12.31 L | 1,625.00 |
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.00 |
| 27 Mar 2025 | bulk | TAU INVESTMENT HOLDINGS PTE LIMITED | SELL | 22.46 L | 1,625.01 |
| 18 Sept 2020 | bulk | THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDEXFD A SERIES OF V I E I F | BUY | 7.07 L | 1,121.89 |
| 02 Nov 2017 | bulk | ASHISH DHAWAN | SELL | 4.72 L | 289.54 |
| 01 Nov 2017 | bulk | ASHISH DHAWAN | SELL | 19.52 L | 288.12 |
Quarterly results · Consolidated · latest 31 Mar 2026
filed 11 May 2026, 09:40 pm IST| ₹ crore | Dec 24* | Mar 25* | Jun 25* | Sept 25* | Dec 25* | Mar 26* |
|---|---|---|---|---|---|---|
| Revenue | 2,969 | 949 | 1,094 | 1,085 | 1,065 | 904 |
| Other income | 24 | 14 | 15 | 15 | 18 | 12 |
| Total expenses | 2,298 | 771 | 837 | 821 | 816 | 754 |
| Operating margin | 27.1% | 23.8% | 27.5% | 28.5% | 27.8% | 19.2% |
| Finance costs | 10 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 125 | 46 | 43 | 44 | 45 | 50 |
| Profit before tax | 694 | 193 | 272 | 279 | 267 | 135 |
| Tax | 180 | 47 | 69 | 71 | 69 | 33 |
| Net profit | 514 | 146 | 202 | 208 | 198 | 101 |
| Net margin | 17.3% | 15.3% | 18.5% | 19.2% | 18.6% | 11.2% |
| EPS (₹) | 33.09 | 9.36 | 12.99 | 13.29 | 12.63 | 6.35 |
Annual results · 12-month figures as filed
| ₹ crore | FY25* | FY26* |
|---|---|---|
| Revenue | 3,918 | 4,148 |
| Other income | 38 | 60 |
| Total expenses | 3,069 | 3,228 |
| Operating margin | 26.3% | 26.0% |
| Finance costs | 12 | 6 |
| Depreciation | 171 | 183 |
| Profit before tax | 887 | 952 |
| Tax | 228 | 243 |
| Net profit | 660 | 709 |
| Net margin | 16.8% | 17.1% |
| EPS (₹) | 42.45 | 45.16 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison